Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Bicycle Therapeutics Reports Interim BT8009 Phase I Clinical Trial Results
Bicycle Therapeutics Limited plc (NASDAQ: BCYC) reported interim Phase I results from the Phase I/II trial of BT8009, a second generation BTC that targets Nectin-4. Results were presented on...